{
    "nct_id": "NCT03935256",
    "official_title": "Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel With Adjuvant Radiotherapy for High Risk Endometrial Cancer",
    "inclusion_criteria": "* Surgically managed endometrial cancer with total or radical hysterectomy with pathology of endometrioid, serous, clear cell or carcinosarcoma histologies\n\n  * Any patient for whom combination of adjuvant radiotherapy and chemotherapy is recommended following pathology review\n\n    * Endometrioid type FIGO Stage I-II with high risk features AND IIIC1, IVA\n    * Serous Carcinoma, Clear Cell Carcinoma, Carcinosarcoma Stage I-IIIC1, IVA\n* ECOG Performance Status 0-2\n* No prior history of pelvic radiotherapy\n* No clinical or radiographic evidence of nodal disease or distant metastases\n* Ability to understand and willingness to sign a written informed consent.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients undergoing irradiation of the para-aortic node chain\n* Prior history of endometrial cancer\n* Prior local radiotherapy for a pelvic malignancy\n* Prior platinum or taxane based chemotherapy for any malignancy\n* Patients receiving any other investigational agents\n* Patients with a known malignancy with a disease free interval < 6 months prior to enrollment\n* Uncontrolled intercurrent illness including but not limited to ongoing or active infection, severely symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that could limit compliance with study requirements\n* Patients enrolled on a competing investigational study.",
    "miscellaneous_criteria": ""
}